Rosen Quoted on Interchangeability and Biosimilar Guidances

07 January 2015 BioWorld Today News

BioWorld Today

Partner David Rosen was quoted in a BioWorld Today article, “FDA: Interchangeability, Other Guidances for Biosimilars in the Works,” on January 7, 2015. The article discussed possible FDA guidance changes on interchangeability, biosimilar draft guidance on labeling, statistical approaches for analyzing similarities in data, and implications of Biologic Price Competition and Innovation Act (BPCIA).

Rosen was quoted saying, “Some of the differences of opinion may be one of the reasons the guidances are a long time in coming. For instance, concerns about the potential market impact of naming and interchangeability guidelines could subject the drafts to the interagency review process.”

Insights

RCE PTA Carve-Out Resumes After Interference
18 September 2019
PharmaPatents
The Ninth Circuit Expected to Rule that Doctors Can Be Wrong in the Winter v. Gardens False Claims Act Case
18 September 2019
Legal News: Government Enforcement Defense & Investigations
Upcoming Webinar: Maximizing Solar Tax Credits - Navigating the Start of Construction Rules (Part 1)
17 September 2019
Renewable Energy Outlook
When Birds Finally Find a Nest
17 September 2019
Dashboard Insights
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.